AstraZeneca's Weekly Myasthenia Shot Has to Beat Its Own C5 Franchise First
The FDA approved Klygefa, a once-weekly subcutaneous C5 inhibitor for generalised myasthenia gravis. Its first commercial job may be pulling patients off AstraZeneca's own C5 products while an FcRn rival grows 54%.
AstraZeneca opened the week with a regulatory win. On 16 November 2026 the company announced that the US Food and Drug Administration approved Klygefa (gefurulimab) for adults with generalised myasthenia gravis whose disease is anti-acetylcholine receptor, or AChR, antibody positive, according to the company's release.
The drug is a weekly self-injection. AstraZeneca describes it as the first and only dual-binding nanobody C5 inhibitor. C5 is a protein in the terminal complement cascade, and the drug's concurrent binding to serum albumin extends its half-life enough to allow once-weekly subcutaneous dosing through an autoinjector. The company estimates that about 98,500 people in the US are diagnosed with the disease, of whom 81,000 are AChR-positive, figures it attributes to data on file.
What the trial showed
The approval rests on the pivotal PREVAIL Phase III trial, which enrolled 260 patients across 20 countries. The primary endpoint was the change from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score at week 26 versus placebo. The treatment difference came in at -1.6, with a 95% confidence interval of -2.4 to -0.8 and a p-value below 0.0001, and AstraZeneca said clinical improvement appeared as early as week one.
On safety, the company said Klygefa was generally well tolerated and that its profile was consistent with previous trials of the C5 inhibitors eculizumab and ravulizumab in the disease. Treatment emergent adverse event rates were similar between the Klygefa and placebo arms, most events were mild or moderate, and the most common in the Klygefa arm were injection site reactions at 12%, back pain at 8% and vomiting at 5%.
The first patients to convert are AstraZeneca's own
The awkward arithmetic sits inside AstraZeneca's own books. Its C5 franchise, sold through Alexion, AstraZeneca Rare Disease, already treats this population with two products. Ultomiris brought in $4,016 million in the first nine months of 2026, up 16% at constant exchange rates, while Soliris generated $1,076 million, down 26% at constant exchange rates, according to the company's results. AstraZeneca attributes the Soliris decline to conversion of patients to Ultomiris across all indications, and attributes part of Ultomiris's growth to that same conversion. The company has already run one conversion machine. Klygefa asks it to run another, this time aimed at both of its existing products.
That is not an unfamiliar playbook for Alexion, which AstraZeneca describes as the first to translate the biology of the complement system into medicines and which is headquartered in Boston. But every prior conversion kept patients on the same target and changed the molecule. Klygefa keeps the mechanism and changes the delivery: a weekly self-injection instead of an infusion. Whether convenience alone moves established patients is the question the franchise's own revenue trajectory will answer.
The class that is actually growing
The competitive pressure, meanwhile, is coming from a different mechanism. argenx's VYVGART, an antibody fragment that binds the neonatal Fc receptor and reduces circulating IgG autoantibodies, posted product net sales of $1,721 million in the third quarter of 2026, up 54% year over year, with $4,534 million for the first nine months against $2,866 million a year earlier, per its filing. Those figures span the full franchise, which covers both gMG and chronic inflammatory demyelinating polyneuropathy, so they are not a pure gMG read.
argenx describes VYVGART as the first-and-only approved treatment for all adult patients living with gMG, and it is not standing still on convenience either: a VYVGART Hytrulo autoinjector is expected to launch in the second half of 2027 across all approved indications. By then, if that launch goes to plan, both companies would be offering patients a self-injected option, one acting on complement and the other on IgG recycling.
Klygefa's US approval follows clearances in the EU, Japan and other countries for certain adults with gMG, with submissions based on PREVAIL under review in China and elsewhere. But the American launch defines the commercial test. AstraZeneca has built a franchise on keeping myasthenia patients inside the complement pathway, and now it must defend that mechanism with its own weekly injection, while the fastest-growing treatment in the disease prepares to hand patients a device of its own.




